johnson johnson

Johnson & Johnson says its vice president and general counsel Russ Deyo will retire next year after 27 years with the company.

Cancer patients relying on Johnson & Johnson's drug Doxil could continue facing shortages after a contract manufacturer suspended operations at its Ohio plant, according to The Wall Street Journal.

Two chemicals considered harmful to babies remain in Johnson & Johnson's baby shampoo sold in the U.S., even though the company already makes versions without them, according to a coalition of health and environmental groups.

Johnson & Johnson is recalling about 200,000 syringes of the anemia drug Eprex because of inconsistent potency in dosages.

Johnson & Johnson says it has agreed to settle a single misdemeanor criminal charge related to a multi-year government investigation into the marketing of its psychiatric drug Risperdal.

Johnson & Johnson has agreed to buy the medical equipment maker Synthes for $21.3 billion in cash and stock, in one of the biggest deals ever in the health care sector.

Strong earnings from Johnson & Johnson helped stocks rebound Tuesday, a day after suffering their worst one-day drop in more than a month.

Johnson & Johnson rose 3.7 percent, leading the 30 companies in the Dow Jones industrial average, with earnings that beat Wall Street's expectations.

Johnson & Johnson is giving Chief Executive William Weldon a small raise this year but cut his annual bonus for 2010, after two years of revenue declines and high-profile recalls.

Stocks fell on Tuesday as disappointing earnings from blue chips such as 3M and Johnson & Johnson prompted investors to pause in the recent rally.

The drug maker has a daunting task: to persuade consumers to buy its name-brand drugs, despite a string of recalls and quality concerns.